… The median percentage of sickled red cells declined from baseline in patients receiving
voxelotor 500 mg (−56.4% change), 700 mg (−45.9% change), and 1000 mg (−45.7% change). …

… in increasing hemoglobin concentration and decreasing hemolysis in patients with sickle
cell disease ages 12 and older. A summary of the completed clinical trials is presented in Table …

… the disease. This retrospective review provides real-world response analysis from a large
cohort of patients being treated with the first-in-class agent voxelotor … in their patient population. …

… study of voxelotor in adult healthy volunteers and patients with … voxelotor (500-1000 mg
per day) in patients with sickle cell … pharmacodynamic properties of voxelotor and established …

… of red blood cells (RBCs), being developed as a once-daily oral drug to treat sickle cell
disease (SCD). … and pharmacodynamics of voxelotor in healthy volunteers and SCD patients. …

… The mean increase in hemoglobin level among the participants receiving voxelotor was
consistent across patient subgroups, regardless of concurrent hydroxyurea use or baseline …

… This study uses real-world evidence to assess voxelotor’s effectiveness in SCD patients in
typical clinical practice from 2019 to 2021 using a national medical claims database (N = 3128…

… -world practice, patients treated with voxelotor have shown … also indicates that voxelotor may
ameliorate complications of … patients with disease-modifying agents such as voxelotor may …

… the USA for the treatment of sickle cell disease in patients aged 12 years and older on the
basis of HOPE trial data. To further describe the applicability of voxelotor as a treatment for this …

… on Voxelotor treatment in Sickle Cell Disease (SCD) patients has revealed promising insights
into managing this complex condition. Acting as an HbS polymerization inhibitor, Voxelotor …